of time and resource (Against) Prof Pete Holt St Georges Vascular - - PowerPoint PPT Presentation

of time and resource against
SMART_READER_LITE
LIVE PREVIEW

of time and resource (Against) Prof Pete Holt St Georges Vascular - - PowerPoint PPT Presentation

Debate: surveillance is a waste of time and resource (Against) Prof Pete Holt St Georges Vascular Institute, London Cost Effectiveness Clinical Outcomes QUALITY Patient Safety Patient Experience Key issues in post-EVAR surveillance


slide-1
SLIDE 1

Debate: surveillance is a waste

  • f time and resource (Against)

Prof Pete Holt St George’s Vascular Institute, London

slide-2
SLIDE 2

Clinical Outcomes Patient Safety Cost Effectiveness Patient Experience QUALITY

slide-3
SLIDE 3

Key issues in post-EVAR surveillance

  • Cost
  • Direct & resource use
  • Effectiveness
  • Clinical & cost
  • Delivery
  • Compliance, Access, Acceptability,

Patient Education

  • Modality
  • Time, Cost, Risk to patient,

Diagnostic accuracy

  • Interval presentations
  • Opponent
slide-4
SLIDE 4
slide-5
SLIDE 5

“Surveillance remains mandatory post-EVAR CEUS would have greater cost implications than DUS… CEUS therefore cannot be recommended… DUS performs equivalently to CT with 30% cost reduction, no nephrotoxicity and no radiation”

slide-6
SLIDE 6

“…a 100% probability that EVAR is a cost-effective treatment” “The increased procedural costs of open repair are NOT outweighed by greater surveillance & reintervention costs after EVAR”

slide-7
SLIDE 7

Clinical Outcomes Patient Safety Cost Effectiveness Patient Experience QUALITY

slide-8
SLIDE 8

CARE RATIONING AND SUPPORTING OVERT BIAS POORLY INFORMED DECISIONS,

slide-9
SLIDE 9

A relatively easy Theory

  • Born 1879, Ulm, Germany
  • 1948 – admitted with abdominal pain
  • “Grapefruit-sized” aortic aneurysm
  • Wrapped anteriorly in cellophane
  • 12 April 1955 – readmitted with pain
  • Died 0115, April 18, 1955 (aged 76)

NON-CREDIBLE

slide-10
SLIDE 10

2 4 6 8 10 12 14 10 20 30 40 50 60 70 80 90 100 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

Axis Title

Mortality and rate of EVAR in the UK 2005-2018

%EVAR mortality

  • Expon. (mortality)
slide-11
SLIDE 11

1 2 3 4 5 6 7 8 9 10 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

Death Rate % Year

“The overall in-hospital mortality rates for open and EVAR procedures for the period between 2015 and 2017 were 3.0% and 0.6%, respectively.” EVAR 1: 4.7 v 1.7

slide-12
SLIDE 12

Failure of surveillance results in higher overall mortality and emphasises the importance of routine surveillance. ACM OR 1.43, p<0.0001

slide-13
SLIDE 13

ARM (OR 1.47) ACM (OR 1.81) ACM OR 1.43, p<0.0001

EVAR 1 Trial <1:10 surviving patients in surveillance at 8 years

slide-14
SLIDE 14

EVAR SCREEN v. . EVAR 1: : It Its not ju just about the op

slide-15
SLIDE 15
  • Surveillance is necessary
  • High risk, more scans
  • Pre-operative risk
  • Low risk, less scans
  • Personalised schedule

based on risk

81% 77% 73% 67% 96%

Attitude and Views to Risk

  • Ultrasound vs CT

69%

Modality Preference

Post-EVAR Patient Preference Study

slide-16
SLIDE 16

Surveillance can be improved but saves lives

  • Improve surveillance programmes
  • Define optimal intervals
  • Risk-based, dynamic

& personalised surveillance

  • Delivery close to home
  • Reliable, safe, non-toxic, non-carcinogenic
  • Investigate and rectify problems early
  • Sac size increase is pathological
  • I/III Endoleaks are clinical urgencies

Clinical Outcomes Patient Safety Cost Effectiveness Patient Experience QUALITY

slide-17
SLIDE 17